HAE - Haemonetics Corp Stock Price, Fair Value and News

91.12USD+0.52 (+0.57%)Market Closed

Market Summary

USD91.12+0.52

Market Closed

0.57%

HAE Alerts

1 major insider sales recently.

HAE Stock Price

View Fullscreen

HAE RSI Chart

HAE Valuation

Market Cap

4.6B

Price/Earnings (Trailing)

39.41

Price/Sales (Trailing)

3.54

EV/EBITDA

19.45

Price/Free Cashflow

40.13

HAE Price/Sales (Trailing)

HAE Profitability

EBT Margin

11.60%

Return on Equity

12.25%

Return on Assets

5.35%

Free Cashflow Yield

2.49%

HAE Fundamentals

HAE Revenue

Revenue (TTM)

1.3B

Rev. Growth (Yr)

12.77%

Rev. Growth (Qtr)

2.09%

HAE Earnings

Earnings (TTM)

117.6M

Earnings Growth (Yr)

-30.68%

Earnings Growth (Qtr)

-34.81%

Breaking Down HAE Revenue

Last 7 days

4.7%

Last 30 days

8.7%

Last 90 days

-0.4%

Trailing 12 Months

-2.8%

How does HAE drawdown profile look like?

HAE Financial Health

Current Ratio

2.56

Debt/Equity

0.83

Debt/Cashflow

0.23

HAE Investor Care

Shares Dilution (1Y)

0.78%

Diluted EPS (TTM)

2.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.3B	0	0	0
2023	1.2B	1.2B	1.2B	1.3B
2022	993.2M	1.0B	1.1B	1.1B
2021	870.5M	903.4M	933.8M	953.2M
2020	988.5M	945.6M	902.5M	883.9M
2019	967.6M	976.7M	987.7M	999.3M
2018	903.9M	922.3M	938.5M	951.8M
2017	886.1M	887.1M	892.2M	898.4M
2016	908.8M	905.4M	905.9M	900.4M
2015	910.4M	899.3M	891.4M	893.0M
2014	938.5M	943.5M	935.3M	925.0M
2013	892.0M	935.1M	952.6M	947.4M
2012	727.8M	733.8M	772.5M	828.7M
2011	676.7M	684.2M	696.8M	711.2M
2010	645.4M	654.4M	664.1M	675.8M
2009	597.9M	609.8M	621.7M	633.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

CEO	Mr. Christopher A. Simon
WEBSITE	haemonetics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	3034

Haemonetics Corp Frequently Asked Questions

What is the ticker symbol for Haemonetics Corp? What does HAE stand for in stocks?

HAE is the stock ticker symbol of Haemonetics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Haemonetics Corp (HAE)?

As of Thu Jul 25 2024, market cap of Haemonetics Corp is 4.61 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HAE stock?

You can check HAE's fair value in chart for subscribers.

Is Haemonetics Corp a good stock to buy?

The fair value guage provides a quick view whether HAE is over valued or under valued. Whether Haemonetics Corp is cheap or expensive depends on the assumptions which impact Haemonetics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HAE.

What is Haemonetics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, HAE's PE ratio (Price to Earnings) is 39.18 and Price to Sales (PS) ratio is 3.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HAE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Haemonetics Corp's stock?

In the past 10 years, Haemonetics Corp has provided 0.096 (multiply by 100 for percentage) rate of return.